Announcements Trials
Browse Landscape

Phase

Phase 1 11Phase 2 8Phase 3 4Phase 1/2 2

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Hepatocellular 2Rectal Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × brivanib × Clear all
NCT00640471 2023-08-04

Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

Canadian Cancer Trials Group

Phase 3 Completed
750 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00908752 2019-12-02

BRISK TA

Bristol-Myers Squibb

Phase 3 Completed
734 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00825955 2019-10-09

BRISK PS

Bristol-Myers Squibb

Phase 3 Completed
587 enrolled
Gastrointestinal

Liver Neoplasms

NCT01108705 2015-10-12

BRISK-APS

Bristol-Myers Squibb

Phase 3 Terminated
87 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡